Baxter International

Close the acquisition of Transderm Scop rights

Delivered by the deadline

Under re-examination This entry has been challenged and is being re-checked against the sources.

Announced: 29 Apr 2021
Due: 30 Jun 2021
Delivered: March 2021

Deadline
Met
Late
Not met
Today

What the company said

“We expect the transaction to close late in the first quarter or early in the second quarter of 2021, subject to the satisfaction of closing conditions.”

SourceBaxter International Form 8-K press release, 2021-04-29
FilingSEC filing index
Deadline as statedlate in the first quarter or early in the second quarter of 2021
Deadline used30 Jun 2021, the last day of the stated period
TypeTransaction
Permanent referenceKI-C-2021-BAX-005257
Cite as https://keptindex.org/c/KI-C-2021-BAX-005257/ — this address never changes.

What we found

Evidence strength A What the grades mean

Baxter acquired the rights to Transderm Scop in March 2021, which falls within the first quarter of 2021, meeting the stated deadline.

A
Baxter International 10-Q filed 2021-07-29 Regulatory filing · published 29 Jul 2021 · retrieved 8 Oct 2026 · kept permanently by the SEC · fingerprint 7ab105d5b198
“In March 2021, we acquired the rights to Transderm Scop (TDS) for the U.S. and specified territories outside of the U.S. from subsidiaries of GlaxoSmithKline” ✓ confirmed on the page

Checked 8 Oct 2026.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Acquisition close
Indicative materiality: High rules
Action: Close
Deliverable: acquisition of Transderm Scop rights
Where: U.S.
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: High
Conditional: Yes: subject to the satisfaction of closing conditions
Depends on: Counterparty

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.

Confirmed. This outcome counts towards the company's Kept Score. How verification works

Are you Baxter International? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-BAX-005257 · Corrections policy